Trials / NCT07282457
Prospective, Randomized, Sham-controlled, Dose-finding I/II Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)
Not yet recruiting Phase 1 / Phase 2 Optogenetics, Gene therapy
- Sponsor
- Augelux Therapeutics
- Treatment
- ZM-02 (low dose); ZM-02 (high dose); ZM-02 (selected dose); Sham injection
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa (RP)
- Ages
- 6 Years to 60 Years
- Enrollment
- 21 participants
- Started
- 2026-06-25
- Main results expected
- 2029-12-25
- Results posted
- Not yet
- Record last updated
- 2026-04-13
What the study is testing
This is a Phase 1/2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).
Where it runs
No sites listed yet.